News

Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst Studies Showing Improvements in Weight-Related Effects of Glucocorticoid ...
Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductions ...
Neurocrine Biosciences Presented One-Year Data From Phase 3 Cahtalysttm Studies Showing Improvements In Weight-Related Effects Of Glucocorticoid Treatment At The 2025 Endocrine ...
Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clin ...